Answer Summary

Members shared their shock at the extreme costs of amyloidosis treatments, with Vyndamax costing roughly $250,000 annually and Onpattro... Read more

Members shared their shock at the extreme costs of amyloidosis treatments, with Vyndamax costing roughly $250,000 annually and Onpattro reaching up to $400,000 per year, with individual infusion sessions billed at $58,000 to $64,000 each. Several members offered crucial guidance on financial assistance, including Pfizer's Vyndalink Patient Assistance Program for those earning below 5 times the Federal Poverty Level (around $98,600 for a family of two), the Healthwell Foundation's grants for Medicare patients with cardiomyopathy, and hospital-based grant coordinators who can help navigate copay assistance programs. A recurring theme was disbelief at the astronomical costs coupled with gratitude for the life-saving support provided by patient assistance programs, with many members successfully securing coverage that reduced their out-of-pocket expenses from thousands of dollars to zero.